5-Amino-1MQ: NNMT Inhibitor Mechanism, Fat Cell Metabolism & Dosage Research

What Is 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium, CAS 847952-38-9) is a small-molecule inhibitor of Nicotinamide N-Methyltransferase (NNMT), an enzyme involved in cellular methylation and NAD+ metabolism. It is not a peptide but a synthetic quinolinium compound investigated for its ability to preserve intracellular nicotinamide and S-adenosylmethionine (SAM) pools. All efficacy evidence is preclinical — no human clinical trial of 5-Amino-1MQ has been published as of August 2026.

Peptigrity's 5-Amino-1MQ compound guide currently carries 143 independent HPLC tests at 99.53% average purity across 226 shops (verified August 2026).

Chemical Structure and Mechanism of Action

It blocks NNMT activity → prevents nicotinamide from being methylated and excreted as 1-methylnicotinamide (1-MNA) → leaves nicotinamide available to the NAD+ salvage pathway and spares SAM, the cell's universal methyl donor. Because NNMT sits at the junction of energy metabolism and epigenetic regulation, inhibiting it shifts both pools at once, as reviewed in "Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation" (Roberti, Fernández & Fraga, Molecular Metabolism, 2021).

5-Amino-1MQ is a quinolinium cation supplied as a salt, which matters for verification: the salt form changes both the mass a lab should see and the amount of active compound per labeled milligram. See TFA vs acetate vs amidate peptide salt forms for why counterions belong on a certificate of analysis.

Discovery and Research Origin

NNMT was validated as an anti-obesity target in 2014, when Barbara B. Kahn's laboratory reported that knocking down Nnmt in white adipose tissue and liver protected mice against diet-induced obesity by increasing cellular energy expenditure — published as "Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity" (Nature, 2014).

The compound itself came out of a medicinal-chemistry program led by Dr. Stanley J. Watowich and Dr. Harshini Neelakantan at the University of Texas Medical Branch at Galveston, with collaborators at UT San Antonio. Their 2018 paper, "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice" (Biochemical Pharmacology), is the foundational 5-amino-1MQ study. Evidence level: cultured adipocytes and mouse models.

Legal Classification and Regulatory Status

Not approved for human use by the FDA, EMA, or TGA Australia. Sold as a research chemical only, with no registered clinical trial program in any indication as of August 2026.

Two points buyers routinely get wrong. First, 5-Amino-1MQ is not on the FDA's Category 2 compounding list, so the 2026 peptide reclassification that reshaped access to compounds like BPC-157 and ipamorelin does not apply to it — background in the FDA peptide regulation 2025–2026 timeline. Second, 5-Amino-1MQ is not specifically named on the WADA Prohibited List, but WADA's S0 (Non-Approved Substances) category prohibits any substance with no current approval for human therapeutic use at all times in sport — which covers it. Athletes in tested sport should treat it as prohibited and confirm with their governing body. Country-by-country context in are peptides legal: regulatory status by country.

5-Amino-1MQ belongs to a broader class of metabolic compounds alongside GLP-1 receptor agonists and AMPK activators. For a complete overview of fat loss mechanisms across all metabolic peptides, see our weight loss and metabolic peptides pillar.

How Does 5-Amino-1MQ Work Biologically?

5-Amino-1MQ works by blocking a single enzymatic reaction: NNMT's transfer of a methyl group from SAM onto nicotinamide. That reaction is a metabolic sink — once nicotinamide becomes 1-MNA it is no longer readily available for NAD+ salvage, and the SAM methyl group is spent. Inhibiting NNMT preserves both pools in tissues where the enzyme is highly expressed, principally white adipose tissue. Evidence level: cell culture and mouse models; no human pharmacodynamic data exists.

NNMT Enzyme Inhibition Pathway

In cultured adipocytes, methylquinolinium NNMT inhibitors including 5-amino-1MQ lowered intracellular 1-MNA, raised both NAD+ and SAM, and suppressed lipogenesis, per the 2018 Biochemical Pharmacology study. The same paper characterised the compound's membrane permeability using parallel artificial membrane and Caco-2 assays, and confirmed selectivity for NNMT over related methyltransferases — the two properties that separate 5-amino-1MQ from earlier NNMT inhibitors that worked in a tube but not inside a cell.

Downstream Metabolic Effects

• Preserved nicotinamide feeds NAMPT, the rate-limiting enzyme of the NAD+ salvage pathway

• Preserved SAM maintains the methyl-donor supply used in DNA and histone methylation

• Suppressed lipogenesis in adipocytes — the cells build less new fat

Tissue-Specific Impact

• Adipose tissue: reduced white-adipose mass and smaller adipocytes in diet-induced obese mice

• Liver: reduced hepatic fat accumulation in mouse studies combining NNMT inhibition with dietary change

• Systemic: lowered plasma total cholesterol in treated mice, with no change in food intake

Downstream sirtuin and mitochondrial effects are frequently claimed for this compound. Those are mechanistic inferences from the NAD+ pathway, not measured outcomes for 5-Amino-1MQ in humans — treat them accordingly.

The NAD+ salvage pathway targeted by 5-Amino-1MQ intersects with the same cellular longevity mechanisms studied for mitochondrial peptides like SS-31 and MOTS-C. Explore the full longevity landscape in our immune support and longevity peptides pillar and the energy and mitochondrial peptides guide, including MOTS-C mitochondrial exercise-mimetic research and SS-31 (Elamipretide) mitochondrial protection research.

Benefits of 5-Amino-1MQ (Based on Preclinical Studies)

All reported benefits derive from animal studies. No human clinical trials have been completed as of August 2026, and no results have been published for any indication.

Fat Loss and Metabolic Efficiency

In the foundational proof-of-concept experiment, diet-induced obese mice given 20 mg/kg of 5-amino-1MQ subcutaneously three times daily for 11 days lost body weight progressively relative to controls, with reduced white-adipose mass, smaller fat cells, and lower plasma total cholesterol — and no change in total food intake (Neelakantan et al., Biochemical Pharmacology, 2018). The appetite-independent result is the finding that made NNMT interesting as a target: the effect appears to run through adipocyte energy handling rather than through hunger.

This distinguishes NNMT inhibitors from GLP-1 receptor agonists, which suppress appetite centrally and carry human outcome data. For the GLP-1 mechanism and clinical weight loss evidence, see our semaglutide science, weight loss and safety profile and tirzepatide dual GIP/GLP-1 mechanism research.

Combination With Dietary Change

NNMT inhibition plus a low-fat diet drove greater adiposity and weight loss than the diet switch alone in diet-induced obese mice, normalising body composition toward age-matched lean animals — reported in "Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice" (Scientific Reports, 2022). Evidence level: mouse only. No equivalent diet-plus-compound comparison has been run in people.

Metabolic Markers and Fatty Liver

A 2024 study in Diabetes, Obesity and Metabolism assessed 5A1MQ on body composition, metabolic variables, fatty-liver pathology and circulating biomarkers in diet-induced obese mice, and characterised its plasma pharmacokinetics and tissue distribution (Babula et al., 2024). This is currently the most complete preclinical package for the compound — and it is still a mouse package. Co-author Dr. Harshini Neelakantan is affiliated with Ridgeline Therapeutics, indicating an active commercial development pathway but not an approved product.

Claims of lifespan extension, cognitive benefit, or anti-inflammatory action are not supported by published 5-Amino-1MQ data. For NAD+ pathway approaches with their own (mixed) human literature, compare mechanisms in our NAD+ boosters cellular energy and anti-aging research and epithalon telomerase anti-aging science.

Side Effects and Safety Profile

No human safety data for 5-Amino-1MQ exists. There is no Phase 1 trial, no published adverse-event profile, and no dose at which human tolerability has been established. Everything below is inference.

What the Preclinical Record Shows

• The 2018 mouse study reported no observable adverse effects over its 11-day treatment window

• Short rodent studies at fixed doses cannot detect chronic, rare, or slow-onset toxicity

• Rodent-to-human safety translation is unestablished for this compound

Long-Term Unknowns

Chronic NNMT inhibition acts directly on the methyl economy of the cell. Sustained shifts in the SAM:SAH ratio could plausibly affect epigenetic regulation, and NNMT is expressed in liver and several tumour types as well as fat — none of which has been studied in humans on this compound. Teratogenic risk is unknown. Anyone weighing cross-compound risk should read our peptide side effects hub for how adverse events are actually catalogued.

Risk Comparison Table

The first row is deliberately not a like-for-like number. A mouse percentage and a human trial percentage are not comparable data, and presenting them side by side is the single most common error in research-chemical marketing copy.

Dosage and Administration Protocols

No human dose of 5-Amino-1MQ has been established, and Peptigrity does not publish one. The only dosing figure with a published source is the preclinical regimen: 20 mg/kg subcutaneously, three times daily, for 11 days in diet-induced obese mice. Converting that to a human figure by body-weight scaling is not a validated procedure for this compound, because no human pharmacokinetic study exists to anchor the conversion.

Why Rodent-to-Human Scaling Fails Here

Allometric conversion assumes you know the target exposure and the clearance profile in both species. For 5-Amino-1MQ, plasma pharmacokinetics have been characterised in mice only (Babula et al., 2024). Human absorption, half-life, oral bioavailability and tissue distribution are all unmeasured. Community "human equivalent dose" figures circulating in vendor copy and forums are arithmetic performed on an unknown — they are not research findings.

Delivery Methods Sold on the Grey Market

• Oral capsules — the most commonly sold format; oral bioavailability in humans is unmeasured

• Subcutaneous injection — the route used in the mouse studies

• Raw powder — requires precision weighing; the widest scope for dosing error

If You Are Documenting a Protocol

For reconstitution and concentration maths on any research compound, the Peptigrity peptide calculator handles the volume conversions. If you are running a protocol, publishing a protocol log alongside the lab test for your specific vial is the only way community reporting becomes something anyone can check — no 5-Amino-1MQ logs have been published yet.

Stacking Strategies (Community Insights)

Stacking claims for 5-Amino-1MQ come entirely from community reports. No combination involving 5-Amino-1MQ has been studied in a controlled human trial, and no interaction data exists.

Commonly Reported Combinations

• With SR9009: reported by users for endurance; SR9009 is a REV-ERB agonist with no human efficacy data of its own

• With MK-677: reported for recovery and lean-mass retention during a caloric deficit

• With NAD+ precursors such as NMN: mechanistically redundant rather than additive — both target the same salvage pathway from different ends

5-Amino-1MQ also appears as a component of the Mitochondrial Blend sold by some shops. Blend vials are excluded from Peptigrity's purity index because a single HPLC number cannot be attributed across multiple actives — verify each component separately.

Community stacking reports are uncontrolled, unblinded, and unverifiable. They describe what people do, not what works.

Users combining 5-Amino-1MQ with growth hormone secretagogues for body recomposition should verify each compound independently. For GH peptide research, see our growth hormone peptides pillar, ipamorelin selective GH secretagogue research, and CJC-1295 with DAC long-acting GHRH science.

Where to Buy 5-Amino-1MQ Safely (Harm Reduction Guide)

Due to lack of regulatory approval, sourcing carries inherent risks. Harm reduction strategies are essential.

Third-Party Testing Essentials

• Demand a batch-matched HPLC certificate plus mass-spec identity confirmation from an independent lab

• Verify the COA references CAS 847952-38-9 and states the salt form

• Check purity ≥98% — and check the measured quantity against the label, not just the purity figure

That last point is where 5-Amino-1MQ buyers get hurt. Across the tests on file, labelled 50 mg vials have measured anywhere from 36.86 mg (−26.3%) to 53.51 mg (+7%) — at purity figures above 99% in both cases. A vial can be 99.9% pure and still be a quarter short. This is the argument made in full in why a 10 mg vial isn't 10 mg.

Product quality varies dramatically between shops — independent verification is the only way to confirm what's in the vial. Our guide on how to verify peptide quality before you buy provides a step-by-step verification framework. Compare actual HPLC purity results across 529 shops (verified August 2026) in the Peptigrity lab tests database, check composite purity statistics and methodology on the Peptigrity Purity Index, browse independent testing labs, and review peptide shops ranked by trust score.

Red Flags

• No Certificate of Analysis provided, or a COA with no named laboratory

• Claims of "FDA-approved" or "human-grade" — illegal mislabeling

• HPLC purity quoted with no mass-spec identity and no measured net content

Our guide to red flags in peptide certificates of analysis covers the document-level tells, and the peptide testing guide walks through sending your own sample to an independent lab.

Price Reality Check

Per-milligram pricing for lab-tested shops is tracked on the 5-Amino-1MQ price page. Those figures exclude shipping, taxes and customs, coupon codes and bulk discount tiers, multi-vial kits, and any vendor requiring an account to display a price — so the lowest tracked figure is the lowest of the sources we can read, not the lowest you will pay. An outlier low price on a compound this cheap to synthesise is a reason to look harder at the COA, not a bargain.

Real-World User Experiences (Reddit, Podcasts, YouTube)

Community reports on 5-Amino-1MQ are uncontrolled, unblinded, and not verifiable against a lab result. They are worth reading as a record of what people are doing and what they believe they experienced — not as evidence of effect. Self-reported energy and body-composition changes on an unapproved compound are indistinguishable from expectancy effects, concurrent diet change, and normal week-to-week variation without a control.

What Would Make a Report Useful

A community report becomes checkable when three things travel together: the specific vial used, the independent lab test for that batch, and an objective measure recorded over time. That combination is exactly what Peptigrity's protocol logs are for, and no 5-Amino-1MQ log has been published yet.

For questions about a specific shop or batch, the Peptigrity community discussions sit alongside the lab data, with a standing rule against sourcing requests, vendor links, and referral codes.

Alternatives to 5-Amino-1MQ

Several compounds are discussed as alternatives, with very different evidence behind them.

Pharmaceutical Options

• Semaglutide: stronger and human-proven fat loss, requires a prescription, causes nausea. See semaglutide science, weight loss and safety profile.

• Metformin: improves insulin sensitivity, decades of human data, GI side effects

Dietary Polyphenols

• Resveratrol and quercetin are sometimes marketed as natural NNMT inhibitors. In-vitro interactions have been reported, but neither has in-vivo NNMT-inhibition data comparable to 5-amino-1MQ, and published potency figures vary too widely between assays to state a meaningful comparison.

Comparison Chart

A note on a compound frequently confused with this one: AICAR is an AMPK activator (CAS 2627-69-2), a different molecule with a different mechanism. It is not an NNMT inhibitor and there is no combined "AICAR-MQ" compound. Vendor listings that merge the two are a labelling error worth treating as a quality signal.

FAQ's

Is 5-Amino-1MQ a peptide?

No. 5-Amino-1MQ (5-amino-1-methylquinolinium, CAS 847952-38-9) is a small-molecule quinolinium compound, not a peptide or growth factor. It is grouped with peptides in research-chemical catalogs because of an overlapping buyer audience, but it is structurally and pharmacologically distinct. For a foundational understanding of what peptides are, see our complete scientific guide to peptides.

Can you buy 5-Amino-1MQ legally?

It is unapproved for human use by the FDA, EMA, and TGA Australia. It is sold as a research chemical with no legal status for human consumption in most jurisdictions. Review 5-Amino-1MQ shop availability and purity data on our platform.

Does 5-Amino-1MQ increase testosterone?

No effect on androgen levels has been reported. Its studied action is metabolic — NNMT inhibition and preservation of NAD+ and SAM pools in fat tissue (Neelakantan et al., 2018). Evidence level: mouse and cell culture.

How fast do results appear?

Unknown in humans. In the 11-day mouse proof-of-concept study, body-weight differences from control became statistically significant around day 6 of three-times-daily dosing. That is a mouse timeline at a mouse dose and does not translate to a human expectation.

Do I need post-cycle therapy (PCT)?

Not applicable. 5-Amino-1MQ has no reported effect on the HPTA and does not alter hormone production like anabolic agents. This is not a statement of safety — it means the specific PCT rationale does not apply.

What Experts Say About 5-Amino-1MQ

No clinical guideline, professional society, or regulator recommends 5-Amino-1MQ for any use. What follows is what the published researchers have actually demonstrated.

Target Validation: Prof. Barbara B. Kahn

Kahn's group at Beth Israel Deaconess Medical Center and Harvard Medical School showed that NNMT is elevated in the white adipose tissue and liver of obese and diabetic mice, and that knocking it down protects against diet-induced obesity by augmenting cellular energy expenditure — concluding that NNMT is a target worth pursuing for obesity and type 2 diabetes (Nature, 2014). That paper is why the field exists; it studied gene knockdown, not this compound.

Compound Development: Dr. Stanley J. Watowich and Dr. Harshini Neelakantan

The UTMB Galveston group demonstrated that 5-amino-1MQ crosses cell membranes, selectively inhibits NNMT, suppresses lipogenesis in cultured adipocytes, and reverses high-fat-diet-induced obesity in mice without changing food intake (Biochemical Pharmacology, 2018). Their subsequent work extended this to fatty-liver endpoints and mouse pharmacokinetics (Diabetes, Obesity and Metabolism, 2024).

What No Expert Has Said

Nobody has published a human dose, a human safety profile, or a human efficacy result for 5-Amino-1MQ. Any vendor page, podcast clip, or forum post presenting one is presenting an extrapolation. The honest summary is that the mechanism is real, the mouse data is real and replicated, and the human evidence does not exist yet.

When to Stop or Consult a Doctor

Discontinuation Triggers

• Any unexplained symptom that begins after starting the compound

• Abnormal liver enzymes on routine bloodwork

• Skin rash, swelling, or any allergic-type reaction

Medical Consultation Recommended If

• You have a history of liver disease

• You take other metabolic agents, including diabetes medication

• You are pregnant, breastfeeding, or planning pregnancy — teratogenic risk is unknown

Because there is no established human safety profile, there is also no validated monitoring schedule. Anyone using an unapproved compound should be under the care of a clinician who knows they are using it.

Whether you are looking at NNMT inhibitors for metabolic research, GLP-1 peptides for weight management, or mitochondrial peptides for longevity, the quality of the source determines what you actually have. Browse our peptide guides across 118 compounds, compare shops through independent lab tests, and review community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides and research compounds discussed may be investigational and are not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.